Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that Litfulo improved hair regrowth in patients aged 12 and older with severe alopecia areata but did not meaningfully improve anxiety or depression symptoms compared to placebo.

This abstract does not report results but indicates that the supplementary material includes comprehensive methodology, additional results, statistical analyses, discussion, and limitations of the Alopecia Areata Relapse Study Group's findings as presented in the main manuscript.

In this study, researchers found that minoxidil sulfate enhances the anti-inflammatory effects of the JAK inhibitor baricitinib in alopecia areata, modulating inflammatory signals and preserving immune privilege features in human hair cells, which suggests potential benefits for combined therapy.

Baricitinib effectively stops hair loss and promotes regrowth in acute alopecia areata.

In this case study, an 11-year-old girl with severe alopecia areata experienced complete hair regrowth and unexpected white-to-black hair repigmentation after switching from baricitinib to ritlecitinib, suggesting that prolonged Janus kinase inhibition may aid both hair and pigment restoration in severe pediatric cases.

This study describes a new treatment algorithm for alopecia areata that includes both disease severity and quality-of-life considerations, highlighting recent therapeutic advances and the need for future validation and access equity.

This review reports that Janus kinase inhibitors and regenerative therapies, such as exosomes and platelet-rich plasma, significantly improve scalp hair regrowth in moderate-to-severe alopecia areata, though challenges like high relapse rates and socioeconomic barriers remain, underscoring the need for personalized treatment protocols.

JAK inhibitors are generally safe for treating alopecia areata.

This study evaluated the use of JAK inhibitors in patients with alopecia areata episodes lasting at least eight years and found that while the overall therapeutic response was limited, a subset of patients achieved meaningful hair regrowth, suggesting these treatments as a viable option.

This review highlights the potential for JAK inhibitors to effectively treat inflammatory and autoimmune skin diseases by targeting the JAK-STAT signaling pathway, advocating for an integrated approach to enhance targeted therapy.

This review highlights advancements in the understanding and treatment of alopecia areata, noting that the approval of oral Janus kinase inhibitors like baricitinib and ritlecitinib marks a significant development in managing severe cases of this autoimmune condition.

This paper reviews existing and emerging therapies for alopecia areata, describing the impact of targeted treatments in this field, and introduces a global network of disease registers to study the long-term safety and effectiveness of these new options.

This review compiles current insights into alopecia areata's epidemiology, immune mechanisms, diagnosis, treatment options, including novel JAK inhibitors, and its severe psychosocial impact, while also highlighting emerging research areas.

This source reviews alopecia areata, highlighting its epidemiology, immune-related causes, diagnostic methods, and the shift in treatment with JAK inhibitors like baricitinib and ritlecitinib, marking the first disease-modifying options for this hair loss condition.

This review discusses the role of JAK inhibitors in treating atopic dermatitis, alopecia areata, and vitiligo, highlighting their effectiveness and safety considerations but stressing the need for further research on long-term safety and patient selection.

This report highlights that oral Janus kinase inhibitors, including baricitinib, ritlecitinib, deuruxolitinib, and brepocitinib, show promise for treating alopecia areata by promoting substantial hair regrowth with mild-to-moderate side effects, positioning them as a favorable alternative to corticosteroids.

This research aims to address gaps in understanding alopecia areata by evaluating the real-world effectiveness and safety of baricitinib, identifying predictors of therapeutic response, and exploring the long-term impact on life quality, including sexual health. Results are not reported in the abstract.

This narrative review highlights the shared immunopathogenesis of alopecia areata and atopic dermatitis and discusses approved and investigational therapies that target common pathways, suggesting a future for personalized treatment strategies.

This review concluded that JAK inhibitors are effective in achieving meaningful hair regrowth in moderate to severe alopecia areata, although continuous therapy is often needed to maintain the benefits.

This review discusses the use of Janus kinase inhibitors for severe alopecia areata in Japan, noting their effectiveness in some patients but highlighting the need for new therapies due to non-responsiveness and relapse in others; it reports no new clinical results.

This article highlights the rising interest in Janus kinase inhibitors for alopecia areata, especially following the FDA approval of baricitinib, underscoring the need for better patient education and physician guidance in selecting appropriate treatments for hair loss.

Medicaid coverage for alopecia areata treatments is inconsistent and often limited.

In this case report, a 30-year-old woman with myasthenia gravis developed vitiligo and alopecia universalis during long-term rituximab therapy. Discontinuation of rituximab and initiation of oral baricitinib led to improvement in skin conditions, underscoring potential immune-related skin effects from rituximab.

The authors concluded that FDA-approved JAK inhibitors, shown to be safe and effective in phase 3 trials, are promising treatment options for severe alopecia areata.

In this case report, a 30-year-old woman with myasthenia gravis developed vitiligo and alopecia universalis during long-term rituximab therapy, suggesting a rare association between the drug and these immune-mediated skin conditions, highlighting the potential benefit of early intervention with baricitinib.

Using molecular dynamics simulations, this study explored the uptake processes of JAK inhibitors on stratum corneum and hair follicle membranes, revealing a unique interaction mechanism in the hair follicle and offering insights into transdermal drug delivery pathways.

Cedrol promotes hair growth better than baricitinib by regulating immune cells.

This review reports that ritlecitinib, baricitinib, and deuruxolitinib, all JAK inhibitors, are effective treatments for moderate-to-severe alopecia areata, with differences in selectivity and onset of action, and suggests that emerging biologic therapies may enhance treatment by offering more targeted immune modulation.

This study observed that patients using dupilumab for atopic dermatitis or chronic rhinosinusitis with nasal polyps may experience new-onset or worsening paradoxical alopecia areata, potentially due to unopposed Th1/Th17 immune activity following Th2 pathway blockade.

This review examines various pharmacological options for managing alopecia areata, highlighting the effectiveness of corticosteroids for mild to moderate cases and promising results from JAK inhibitors like baricitinib for more severe forms, with additional benefits from minoxidil and potential from other treatments.